B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2018

Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2018’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia

– The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects

– The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Aduro BioTech Inc

AstraZeneca Plc

Bayer AG

BioInvent International AB

Celgene Corp

Cell Source Inc

Chugai Pharmaceutical Co Ltd

Dynavax Technologies Corp

Elsalys Biotech SA

GammaDelta Therapeutics Ltd

iDD biotech SAS

Immunomedics Inc

Juno Therapeutics Inc

Loxo Oncology Inc

MEI Pharma Inc

Millennium Pharmaceuticals Inc

Molecular Templates Inc

Nordic Nanovector ASA

Novartis AG

Noxxon Pharma AG

Ono Pharmaceutical Co Ltd

Portola Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Samumed LLC

Sunesis Pharmaceuticals Inc

TheraMAB LLC

Unum Therapeutics Inc

Xencor Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

B-Cell Chronic Lymphocytic Leukemia Overview

B-Cell Chronic Lymphocytic Leukemia Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

B-Cell Chronic Lymphocytic Leukemia Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

B-Cell Chronic Lymphocytic Leukemia Companies Involved in Therapeutics Development

AB Science SA

Aduro BioTech Inc

AstraZeneca Plc

Bayer AG

BioInvent International AB

Celgene Corp

Cell Source Inc

Chugai Pharmaceutical Co Ltd

Dynavax Technologies Corp

Elsalys Biotech SA

GammaDelta Therapeutics Ltd

iDD biotech SAS

Immunomedics Inc

Juno Therapeutics Inc

Loxo Oncology Inc

MEI Pharma Inc

Millennium Pharmaceuticals Inc

Molecular Templates Inc

Nordic Nanovector ASA

Novartis AG

Noxxon Pharma AG

Ono Pharmaceutical Co Ltd

Portola Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Samumed LLC

Sunesis Pharmaceuticals Inc

TheraMAB LLC

Unum Therapeutics Inc

Xencor Inc

B-Cell Chronic Lymphocytic Leukemia Drug Profiles

202-b Drug Profile

Product Description

Mechanism Of Action

R&D Progress

2X-121 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-8779 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACTR-707 + rituximab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alemtuzumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisertib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aurixim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4573 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Betalutin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-1206 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BION-1301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Chronic Lymphocytic Leukemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Hematological Malignancies Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD19 for B-Cell Malignancies Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD19 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

copanlisib hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DTRMWXHS-12 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELB-021 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDD-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDD-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenalidomide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LOXO-305 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ME-401 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-3724 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olaptesed pegol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-1979 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SD-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-08502 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAB-08 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirabrutinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tisagenlecleucel Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vecabrutinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-13676 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-Cell Chronic Lymphocytic Leukemia Dormant Projects

B-Cell Chronic Lymphocytic Leukemia Discontinued Products

B-Cell Chronic Lymphocytic Leukemia Product Development Milestones

Featured News & Press Releases

Oct 24, 2017: Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma

Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement

Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by AB Science SA, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Aduro BioTech Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by AstraZeneca Plc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Bayer AG, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by BioInvent International AB, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Celgene Corp, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Cell Source Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Dynavax Technologies Corp, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Elsalys Biotech SA, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by GammaDelta Therapeutics Ltd, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by iDD biotech SAS, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Immunomedics Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Juno Therapeutics Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Loxo Oncology Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by MEI Pharma Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Millennium Pharmaceuticals Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Molecular Templates Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Nordic Nanovector ASA, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Novartis AG, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Noxxon Pharma AG, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Portola Pharmaceuticals Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Samumed LLC, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Sunesis Pharmaceuticals Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by TheraMAB LLC, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Unum Therapeutics Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Xencor Inc, H2 2018

B-Cell Chronic Lymphocytic Leukemia Dormant Projects, H2 2018

B-Cell Chronic Lymphocytic Leukemia Dormant Projects, H2 2018 (Contd..1), H2 2018

B-Cell Chronic Lymphocytic Leukemia Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports